
Nexalin Initiates Q-Submission Process for Transcranial Alternating Current Stimulation Device in Alzheimer Studies
Following positive conversations with the FDA, Nexalin plans to submit a Q-Submission to the agency for its Gen-2 SYNC system, a non-invasive neuromodulation device that does not require anesthesia or sedation. Through this, the company will work with the …